Rezolute, Inc. (RZLT)
4.02
+0.15
(+3.88%)
USD |
NASDAQ |
Nov 10, 16:00
4.015
0.00 (0.00%)
After-Hours: 20:00
Rezolute Enterprise Value : 299.58M for Nov. 10, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 10, 2026 | 299.58M |
| November 09, 2026 | 285.07M |
| November 06, 2026 | 286.04M |
| November 05, 2026 | 262.82M |
| November 04, 2026 | 293.78M |
| November 03, 2026 | 298.61M |
| November 02, 2026 | 286.04M |
| October 30, 2026 | 292.81M |
| October 29, 2026 | 309.25M |
| October 28, 2026 | 318.92M |
| October 27, 2026 | 308.28M |
| October 26, 2026 | 280.23M |
| October 23, 2026 | 283.62M |
| October 22, 2026 | 284.10M |
| October 21, 2026 | 268.63M |
| October 20, 2026 | 268.63M |
| October 19, 2026 | 268.63M |
| October 16, 2026 | 257.02M |
| October 15, 2026 | 287.97M |
| October 14, 2026 | 319.89M |
| October 13, 2026 | 356.64M |
| October 12, 2026 | 381.79M |
| October 09, 2026 | 381.79M |
| October 08, 2026 | 359.55M |
| October 07, 2026 | 334.40M |
| Date | Value |
|---|---|
| October 06, 2026 | 328.60M |
| October 05, 2026 | 329.56M |
| October 02, 2026 | 298.61M |
| October 01, 2026 | 304.41M |
| September 30, 2026 | 311.19M |
| September 29, 2026 | 287.43M |
| September 28, 2026 | 296.11M |
| September 25, 2026 | 269.12M |
| September 24, 2026 | 272.97M |
| September 23, 2026 | 278.76M |
| September 22, 2026 | 282.61M |
| September 21, 2026 | 270.08M |
| September 18, 2026 | 263.33M |
| September 17, 2026 | 273.94M |
| September 16, 2026 | 276.83M |
| September 15, 2026 | 293.22M |
| September 14, 2026 | 302.86M |
| September 11, 2026 | 299.97M |
| September 10, 2026 | 295.15M |
| September 09, 2026 | 284.54M |
| September 08, 2026 | 317.32M |
| September 04, 2026 | 334.67M |
| September 03, 2026 | 330.82M |
| September 02, 2026 | 332.74M |
| September 01, 2026 | 326.96M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Opus Genetics, Inc. | 350.79M |
| ACADIA Pharmaceuticals, Inc. | 2.254B |
| Alnylam Pharmaceuticals, Inc. | 19.71B |
| Anika Therapeutics, Inc. | 161.61M |
| Savara, Inc. | 911.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.49M |
| Total Expenses (Quarterly) | 18.49M |
| EPS Diluted (Quarterly) | -0.1764 |
| Earnings Yield | -18.59% |
| Normalized Earnings Yield | -18.68 |